Evidence map›Paper›PMID 39474422›Full record

ArticleFrontiers in immunology2024

Single-cell and spatial transcriptome characterize coinhibitory cell-cell communications during histological progression of lung adenocarcinoma.

Judong Luo, Qianman Gao, Meihua Wang, Hui Liu, Hong Zhu

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Judong Luo *Department of Radiotherapy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Qianman Gao *College of Computer and Information Engineering, Nanjing Tech University, Nanjing, Jiangsu, China.
Meihua WangDepartment of Pathology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China.
Hui LiuCollege of Computer and Information Engineering, Nanjing Tech University, Nanjing, Jiangsu, China.
Hong ZhuDepartment of Radiotherapy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lung adenocarcinoma, a prevalent and lethal malignancy globally, is characterized by significant tumor heterogeneity and a complex tumor immune microenvironment during its histologic pattern progression. Understanding the intricate interplay between tumor and immune cells is of paramount importance as it could potentially pave the way for the development of effective therapeutic strategies for lung adenocarcinoma. Methods: In this study, we run comparative analysis of the single-cell transcriptomic data derived from tumor tissues exhibiting four distinct histologic patterns, lepidic, papillary, acinar and solid, in lung adenocarcinoma. Furthermore, we conducted immunofluorescence assay and spatial transcriptomic sequencing to validated the spatial co-localization of typical co-inhibitory factors. Results and Discussion: Our analysis unveiled several co-inhibitory receptor-ligand interactions, including PD1-PDL1, PVR-TIGIT and TIGIT-NECTIN2, that potentially exert a pivotal role in recruiting immunosuppressive cells such as M2 macrophages and Tregs into LUAD tumor, thereby establishing immunosuppressive microenvironment and inducing T cells to exhaustion state. Furthermore, The expression level of these co-inhibitory factors, such as NECTIN2 and PVR, were strongly correlated with low immune infiltration, unfavorable patient clinical outcomes and limited efficacy of immunotherapy. We believe this study provides valuable insights into the heterogeneity of molecular, cellular interactions leading to immunosuppressive microenvironment during the histological progression of lung adenocarcinoma. The findings could facilitate the development of novel immunotherapy for lung cancer.

Indexed as

Adenocarcinoma of LungCell CommunicationDisease ProgressionLung NeoplasmsSingle-Cell AnalysisTranscriptomeTumor MicroenvironmentB7-H1 AntigenGene Expression ProfilingGene Expression Regulation, NeoplasticHumansNectinsProgrammed Cell Death 1 ReceptorReceptors, ImmunologicB7-H1 AntigenNectinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTIGIT protein, humancell-cell interactionshistologic patternimmunofluorescence assayimmunosuppressive microenvironmentscRNA-seqspatial transcriptomics

Identifiers

PMID39474422
PMCPMC11518759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.